Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews...
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • Allergy (Apr 2019)
    • Biology of familial cancer predisposition syndromes (Feb 2019)
    • Mitochondrial dysfunction in disease (Aug 2018)
    • Lipid mediators of disease (Jul 2018)
    • Cellular senescence in human disease (Apr 2018)
    • View all review series...
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Scientific Show Stoppers
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • About
  • Editors
  • Consulting Editors
  • For authors
  • Current issue
  • Past issues
  • By specialty
  • Subscribe
  • Alerts
  • Advertise
  • Contact
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • Brief Reports
  • Technical Advances
  • Commentaries
  • Editorials
  • Hindsight
  • Review series
  • Reviews
  • The Attending Physician
  • First Author Perspectives
  • Scientific Show Stoppers
  • Top read articles
  • Concise Communication
Top
  • View PDF
  • Download citation information
  • Send a letter
  • Terms of use
  • Standard abbreviations
  • Article usage
  • Citations to this article
  • Share this article
  • Need Help? E-mail the JCI
  • Top
  • Abstract
  • Version history

Advertisement

Research Article Free access | 10.1172/JCI116648

Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation.

D M Karussis, U Vourka-Karussis, D Lehmann, H Ovadia, R Mizrachi-Koll, A Ben-Nun, O Abramsky, and S Slavin

Department of Neurology, Hadassah-Hebrew University Hospital, Jerusalem, Israel.

Find articles by Karussis, D. in: JCI | PubMed | Google Scholar

Department of Neurology, Hadassah-Hebrew University Hospital, Jerusalem, Israel.

Find articles by Vourka-Karussis, U. in: JCI | PubMed | Google Scholar

Department of Neurology, Hadassah-Hebrew University Hospital, Jerusalem, Israel.

Find articles by Lehmann, D. in: JCI | PubMed | Google Scholar

Department of Neurology, Hadassah-Hebrew University Hospital, Jerusalem, Israel.

Find articles by Ovadia, H. in: JCI | PubMed | Google Scholar

Department of Neurology, Hadassah-Hebrew University Hospital, Jerusalem, Israel.

Find articles by Mizrachi-Koll, R. in: JCI | PubMed | Google Scholar

Department of Neurology, Hadassah-Hebrew University Hospital, Jerusalem, Israel.

Find articles by Ben-Nun, A. in: JCI | PubMed | Google Scholar

Department of Neurology, Hadassah-Hebrew University Hospital, Jerusalem, Israel.

Find articles by Abramsky, O. in: JCI | PubMed | Google Scholar

Department of Neurology, Hadassah-Hebrew University Hospital, Jerusalem, Israel.

Find articles by Slavin, S. in: JCI | PubMed | Google Scholar

First published August 1, 1993 - More info

Published in Volume 92, Issue 2 on August 1, 1993
J Clin Invest. 1993;92(2):765–772. https://doi.org/10.1172/JCI116648.
© 1993 The American Society for Clinical Investigation
First published August 1, 1993 - Version history
Abstract

A chronic relapsing form of experimental autoimmune encephalomyelitis (CR-EAE) was induced in SJL/J mice by adoptive transfer of lymph node cells (LNC) sensitized to guinea pig myelin basic protein (GMBP). We examined the efficacy of high dose immunosuppressive regimens (cyclophosphamide [CY] 300 mg/kg or total body irradiation [TBI] 900 cGy) followed by syngeneic bone marrow transplantation (SBMT) in prevention and treatment of already established CR-EAE. Treatment with TBI and SBMT on day 5 after the induction of CR-EAE, just before the onset of clinical signs, completely inhibited the appearance of the paralytic signs. The same treatment, applied 4 d after the clinical onset of the disease, led to a significant regression of the paralytic signs and to a total inhibition of spontaneous relapses during a follow-up period of 2 mo. Challenge of mice with GMBP+CFA 78 d after the passive induction of CR-EAE induced a relapse of the disease 7 d later in almost all of the untreated mice; in contrast, the same challenge given to TBI+SBMT-treated mice caused a delayed relapse (30 d later) in only a minority (3/7) of the challenged mice. In vitro lymphocytic proliferative responses to GMBP and purified protein derivative were significantly lower in TBI/SBMT-treated mice before and after the GMBP challenge, although these mice were fully immunocompetent, as evidenced by their normal lymphocytic proliferation to concanavalin A (ConA) and the FACS analysis of their lymphocytic subpopulations. A similar beneficial therapeutic effect was observed in mice treated with CY followed by SBMT, after the onset of CR-EAE. Our results could support possible clinical applications of similar therapeutic strategies, involving acute immunosuppression followed by stem cell transplantation and retolerization of the reconstituting immune cells in life-threatening neurological and multisystemic autoimmune diseases.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 765
page 765
icon of scanned page 766
page 766
icon of scanned page 767
page 767
icon of scanned page 768
page 768
icon of scanned page 769
page 769
icon of scanned page 770
page 770
icon of scanned page 771
page 771
icon of scanned page 772
page 772
Version history
  • Version 1 (August 1, 1993): No description

Article tools

  • View PDF
  • Download citation information
  • Send a letter
  • Terms of use
  • Standard abbreviations
  • Article usage
  • Citations to this article
  • Share this article
  • Need Help? E-mail the JCI

Go to:

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement
Follow JCI:
Copyright © 2019 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts